((自动化翻译由路透提供，请见免责声明 )) (更新)
12月11日 - ** 药物开发商Cellectar Biosciences的 股价下跌约 71% ，创下 37美分的历史新低
** 周二，CLRB 表示可能将 (link) 其实验性 抗癌药物 出售给一家更大的公司或与之合作。
** 该决定是在与美国 FDA 就该药物 的 审批要求进行讨论之后做出的。
** 该公司表示 将裁员 60%，以将其运营跑道延长至 2025 年第三季度。
** 截至2023年12月31日，CLRB共有20名员工--美国证券交易委员会文件
** 包括盘中走势在内，该股今年已下跌86.3%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.